热门资讯> 正文
诺华获得FDA批准Fabhalta用于IgAN患者
2024-08-08 04:57
- Novartis (NYSE:NVS) has received FDA accelerated approval for its drug Fabhalta to be used in the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression, according to the agency’s website.
- According to the product's expanded label, continued approval for the indication could be contingent on a confirmatory clinical trial.
- Fabhalta is already approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH. The product was approved in December 2023.
Other approved drugs for IgAN include Travere Therapeutics’ (TVTX) Filspari and Calliditas Therapeutics’ (CALT) Tarpeyo.
More on Novartis
- Novartis: Another Beat, Another Raise
- Why Novartis Deserves Your Attention After Q2 2024 Results
- Novartis AG (NVS) Q2 2024 Earnings Call Transcript
- Novartis sues FDA for approving Entresto generic
- Novartis' Scemblix granted FDA Priority Review status for front-line CML
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
